Molecular basis of bluetongue virus neutralization

Molecular and serological analyses of bluetongue virus serotypes 10 and 11 and their intertype reassortants indicate that the viral RNA segment L2 codes for the serotype-specific antigen. Individual RNA segments of parental and reassortant viruses were characterized by oligonucleotide fingerprint analyses. Analyses of their virion polypeptides by Cleveland peptide mapping (Cleveland et al., J. Biol. Chem. 252:1102-1106, 1977) demonstrated that the L2 gene segregated colinearly with the viral P2 protein, implicating it as the antigen that is responsible for the viral serotype specificity.

Detection of antibodies to herpes simplex virus in the cerebrospinal fluid of patients with herpes simplex encephalitis

Cerebrospinal fluid (CSF) and serum specimens from patients with presumed herpes simplex encephalitis (HSE) were characterized for antibodies to herpes simplex virus (HSV) by immunoblot and other immunoassays. Specimens from patients proven to have HSE (biopsy-proven) were compared with those from patients with other diseases diagnosed by brain biopsy (biopsy-negative for HSV). Immunoblot of CSF demonstrated that antibodies to HSV-specific polypeptides, particularly to glycoprotein B, were present in a matched serum specimen. When purified glycoprotein B was used to detect CSF antibodies, 34 of 35 specimens from biopsy-proven patients were reactive (97% sensitivity) compared with only six of 22 specimens obtained from biopsy-negative patients (73% specificity). If leakage of antibodies to a marker virus (adenovirus) was determined and controlled, the specificity increased to 100%. These diagnostic assays provide useful tools for the retrospective assessment of CSF specimens obtained from patients with presumed HSE.

Antibody response of the newborn after herpes simplex virus infection

Antibody responses to herpes simplex virus (HSV) types 1 and 2, as determined by enzyme-linked immunoabsorbent assay (ELISA), neutralization, and immunoblot, were assessed in sera from newborns with documented HSV infections. The antibody response of the newborns was defined by disease duration and correlated with disease classification and outcome. Three unique observations were made. First, the quantity of total antibodies at presentation, as determined by ELISA and neutralization, was not predictive of disease classification or outcome. Second, the frequency and intensity of antibody responses to immunologically recognized HSV polypeptides in newborns with central nervous system and disseminated infections were greater than those in newborns with infections localized to the skin, eye, and mouth. Third, the long-term outcome in HSV-infected newborns could be predicted by the quantity of antibodies to the immediate-early infected cell polypeptide ICP 4. These data provide insight into host response to individual polypeptides and their potential value in predicting long-term prognosis.

Insights into renal and urological complications of inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic condition characterized by immune-mediated inflammation in the gastrointestinal tract, which follows a relapsing and remitting course. Apart from affecting the gastrointestinal tract, IBD also has extra-intestinal manifestations (EIMs). While the etiology of extraintestinal manifestation remains unclear, it is theorized to be based on immunological responses influenced by genetic factors. Renal involvement is one of the EIMs observed in ulcerative colitis and Crohn's disease. The renal manifestations in IBD patients encompass a range of conditions including nephrolithiasis, amyloidosis, tubulointerstitial nephritis, glomerulonephritis (GN), obstructive pathologies, and chronic kidney disease (CKD). The incidence of CKD in IBD patients varies from 5%-15%. The decline in renal function can stem from various factors such as direct inflammatory damage to the kidneys leading to glomerular or tubular injury, or from complications like recurrent stones, amyloidosis, or GN. Additionally, nephrotoxic medications used in treating IBD, such as TNF-α inhibitors, calcineurin inhibitors, and aminosalicylates, can exacerbate the decline in renal function. Currently, there is a lack of consensus regarding these patients' screening and renal function monitoring. This review aims to assess the existing literature on the different renal complications among individuals with IBD, shedding light on their pathophysiology and management.